Site-Directed IL-2 PEG Conjugate for Half-Life and Receptor Tuning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing modifications of interleukin 2 (IL-2) for cancer treatment face challenges such as reduced binding ability, immunogenic reactions, high production costs, and complex molecular structures, with conventional PEGylation methods not effectively prolonging the half-life or optimizing receptor binding.
Innovation Solution
A human interleukin 2-polyethylene glycol conjugate is developed by introducing unnatural amino acids at specific sites through codon expansion technology, forming an oxime bond with PEG, which retains IL-2Rβγ binding activity while reducing IL-2Rα binding and prolonging the half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If conventional PEGylation methods are used to modify IL-2, then the molecular structure becomes more complex, but the half-life is not effectively prolonged and receptor binding is not optimized
Solution Approach 1:
The patent applies local quality by introducing unnatural amino acids at specific designated positions in the IL-2 protein sequence rather than random modification. This site-directed approach allows precise control over where PEG conjugation occurs, optimizing both half-life extension and receptor binding properties while avoiding complex global structural changes
Solution Approach 2:
The patent changes the chemical parameters of IL-2 by incorporating unnatural amino acids with specific functional groups (such as alkyne or azide groups) that enable controlled PEG conjugation. This parameter change allows the formation of stable oxime bonds with PEG, achieving prolonged half-life without excessive molecular complexity
2Reliability
If IL-2 is modified to enhance binding with specific receptor complexes, then the binding ability to certain receptors improves, but the binding ability to other receptors (such as IL-2Rα) may be reduced
Solution Approach 1:
The patent uses local quality by making site-directed mutations at specific positions in the IL-2 protein to selectively enhance binding to certain receptor complexes (such as IL-2Rβγ) while maintaining or reducing binding to others (such as IL-2Rα). This localized modification approach allows fine-tuning of receptor specificity
Solution Approach 2:
The patent applies inversion by using unnatural amino acids that can form oxime bonds with PEG, effectively inverting the conventional wisdom that PEGylation always reduces protein activity. Instead, the controlled PEG conjugation at specific sites enhances the desired binding properties and prolongs half-life
3Reliability
If site-directed mutation combined with fusion expression is used to modify IL-2, then the binding ability to specific receptors is improved, but the production cost increases
Solution Approach 1:
The patent changes the amino acid sequence parameters by incorporating unnatural amino acids that can be introduced through codon expansion technology. This approach allows site-directed modification without requiring complex fusion expression systems, potentially reducing production costs while maintaining improved binding ability
Solution Approach 2:
The patent uses unnatural amino acids as intermediaries that facilitate controlled PEG conjugation. These unnatural amino acids serve as handles that enable precise and efficient PEG attachment, simplifying the manufacturing process compared to traditional fusion expression methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate enhances CD8+ T cell proliferation, inhibits Treg cell expansion, and significantly prolongs in vivo half-life, providing effective tumor immunity with improved stability and coupling efficiency.
Implementation Method 1
the PEG is coupled to the at least one unnatural amino acid by forming an oxime bond between the carbonyl terminal group and the PEG containing a hydroxylamine terminal group
Data Source
AI summary
The invention provides a human interleukin 2-polyethylene glycol conjugate and use thereof. The human interleukin 2-polyethylene glycol conjugate provided by the invention comprises a recombinant human interleukin 2 containing at least one unnatural amino acid and PEG coupled to the at least one unnatural amino acid. The unnatural amino acid is a compound containing a carbonyl terminal group and having a structure as shown in formula (I) or an enantiomer thereof, and the PEG is coupled to the at least one unnatural amino acid by forming an oxime bond between the carbonyl terminal group and the PEG containing a hydroxylamine terminal group. The human interleukin 2-polyethylene glycol conjugate provided by the invention can be used individually or in combination with other anti-tumor drugs for the treatment of diseases such as solid tumors and hematologic tumors.